(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
31 October 2002 (31.10.2002)

PCT

(10) International Publication Number
WO 02/085889 A1

(51) International Patent Classification[7]: C07D 401/12, A61K 31/4439, A61P 1/04

(21) International Application Number: PCT/IB02/01350

(22) International Filing Date: 24 April 2002 (24.04.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P-0100111 25 April 2001 (25.04.2001) SI

(71) Applicant *(for all designated States except US)*: **LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D.** [SI/SI]; Legal Affairs and Industrial Property Dept., Verovskova 57, 1526 Ljubljana (SI).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HAFNER, Milaé, Natasa** [SI/SI]; c/o LEK Pharmaceutical and Chemical Company d.d., Legal Affairs and Industrial Property Dept., Verovskova 57, 1526 Ljubljana (SI). **ÈOPAR, Anton** [SI/SI]; c/o LEK Pharmaceutical and Chemical Company d.d., Legal Affairs and Industrial Property Dept., Verovskova 57, 1526 Ljubljana (SI). **PODOBNIK, Barbara** [SI/SI]; c/o LEK Pharmaceutical and Chemical Company d.d., Legal Affairs and Industrial Property Dept., Verovskova 57, 1526 Ljubljana (SI). **CIZERLE, Beléié, Andreja** [SI/SI]; c/o LEK Pharmaceutical and Chemical Company d.d., Legal Affairs and Industrial Property Dept., Verovskova 57, 1526 Ljubljana (SI). **KOSAK, Alenka** [SI/SI]; c/o LEK Pharmaceutical and Chemical Company d.d., Legal Affairs and Industrial Property Dept., Verovskova 57, 1526 Ljubljana (SI). **ORNIK, Brina** [SI/SI]; c/o LEK Pharmaceutical and Chemical Company d.d., Legal Affairs and Industrial Property Dept., Verovskova 57, 1526 Ljubljana (SI). **URLEB, Uros** [SI/SI]; c/o LEK Pharmaceutical and Chemical Company d.d., Legal Affairs and Industrial Property Dept., Verovskova 57, 1526 Ljubljana (SI).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/085889 A1

(54) Title: CRYSTALLINE FORM OF OMEPRAZOLE

(57) Abstract: A novel crystalline form of the substrate known under the chemical name 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny]-1H-benzimidazole, and having the generic name omeprazole, hereinafter referred to as omeprozole form C, is disclosed. Further, a process for the preparation of omeprazole form C, a pharmaceutical formulation containing omeprazole form C in admixture with pharmaceutically acceptable excipients and the use of omeprazole form C for treatment of gastrointestinal disorders are disclosed.